<DOC>
	<DOCNO>NCT02856646</DOCNO>
	<brief_summary>The purpose study gather data patient diagnose treated classical Hodgkin Lymphoma ( cHL ) . It aim closely observe treatment cHL render , well assess outcome treatment option impact quality life . Additional analysis also attempt identify prognostic predictive biomarkers</brief_summary>
	<brief_title>Hodgkin Lymphoma Molecular Profiling Clinical Outcomes U.S. Community Oncology Practices</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Histologically confirm diagnosis Classical Hodgkin Lymphoma ( cHL ) Patients treatmentnaïve , within ± 2 week begin line therapy time enrollment Patients must within ± 2 week Day 1 first cycle line therapy enroll ; cycle practicedefined chemotherapy , target therapy , immunotherapybased regimen . Any Eastern Cooperative Oncology Group ( ECOG ) Karnofsky performance status ( PS ) Patients must available medical record date diagnosis cHL available medical record document prior treatment treatment date Hodgkin lymphoma , include chemotherapy , radiation , surgery anticancer therapy receive . Patients must consent use FFPE tissue block exploratory analysis Patients supportive care receive anticancer therapy eligible enroll Patients unknown date diagnosis cHL Patients whose prior cHL therapy , date therapy ( eg , surgery , radiation , drug therapy ) unknown Any nonHL ( nonHodgkin Lymphoma ) active malignancy patient receive treatment Patients participate clinical study allow enrollment noninterventional study Patients enrol go receive supportive , palliative , hospice , endoflife care remain study discontinue followup . Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>